- The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate AI-based ECG Algorithms
- The collaboration is focused on building next-generation, personalized AI-ECG algorithms for wellness and clinical applications, including assessing heart attack risk
- HeartBeam’s role in this evolving landscape is anchored by its HeartBeam System
HeartBeam (NASDAQ: BEAT) recently announced a collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology, marking another step in the company’s push to expand its role in next-generation cardiac monitoring. The announcement highlights HeartBeam’s growing focus on artificial intelligence (“AI”)-enabled analysis and reinforces the relevance of its technology as healthcare increasingly shifts toward data-driven, remote monitoring solutions.
The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate high value, AI-based ECG algorithms that can be deployed broadly across HeartBeam’s platform. These AI models may include patient-relevant wellness insights, condition-focused…
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
